Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections
- PMID: 35647542
- PMCID: PMC9020770
- DOI: 10.1039/d1md00359c
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections
Abstract
Mycobacterium abscessus (Mab) are rapidly growing mycobacteria that cause severe and persistent infections in both skin and lung tissues. Treatment regimens involve the extended usage of complex combinations of drugs, often leading to severe adverse side effects, particularly in immunocompromised patients. Current macrolide therapies are gradually proving to be less effective, largely due to emergence of antibiotic resistance; there is therefore an increasing need for the discovery of new antibacterials that are active against Mab. This review highlights recent research centred upon a number of potential therapeutic targets from Mab (Ag85C, ClpC1, GyrB, MmpL3 and TrmD), and discusses the various approaches used to discover small molecule inhibitors, in the search for future antibiotics for the treatment of Mab infections.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
There are no conflicts to declare.
Figures











Similar articles
-
Development of Inhibitors against Mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches.J Med Chem. 2019 Aug 8;62(15):7210-7232. doi: 10.1021/acs.jmedchem.9b00809. Epub 2019 Jul 19. J Med Chem. 2019. PMID: 31282680 Free PMC article.
-
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18. mBio. 2019. PMID: 30755518 Free PMC article.
-
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease.mSphere. 2024 Jul 30;9(7):e0038124. doi: 10.1128/msphere.00381-24. Epub 2024 Jul 9. mSphere. 2024. PMID: 38980071 Free PMC article.
-
Alternative therapies against Mycobacterium abscessus infections.Clin Microbiol Infect. 2024 Jun;30(6):732-737. doi: 10.1016/j.cmi.2023.10.001. Epub 2023 Nov 4. Clin Microbiol Infect. 2024. PMID: 37820951 Review.
-
Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections.Clin Microbiol Infect. 2024 Jun;30(6):718-725. doi: 10.1016/j.cmi.2023.09.019. Epub 2023 Oct 4. Clin Microbiol Infect. 2024. PMID: 37797824 Review.
Cited by
-
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.Biomedicines. 2022 Nov 3;10(11):2793. doi: 10.3390/biomedicines10112793. Biomedicines. 2022. PMID: 36359313 Free PMC article. Review.
-
Advances in antibacterial agents for Mycobacterium fortuitum.RSC Med Chem. 2024 Oct 18;16(1):37-49. doi: 10.1039/d4md00508b. Online ahead of print. RSC Med Chem. 2024. PMID: 39493226 Free PMC article. Review.
References
-
- Moore M. Frerichs J. B. J. Invest. Dermatol. 1953;20:133. - PubMed
-
- Griffith D. E. Girard W. M. Wallace Jr R. J. Am. Rev. Respir. Dis. 1993;147:1271. - PubMed
-
- Mycobacteria were initially noted growing on the surfaces of cultures, appearing filamentous under a microscope with resemblance to a mould, hence the Greek prefix myco- (relating to fungi)
Publication types
LinkOut - more resources
Full Text Sources